Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease
- PMID: 16307858
- DOI: 10.1016/j.exger.2005.10.007
Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease
Abstract
A large number of studies deals with the association of cholesterol and Abeta levels, however, the results are so far controversial. Whereas some studies report on increased cholesterol levels, other authors refer to an association of decreased peripheral cholesterol and the incidence of Alzheimer's disease. It is also questionable whether plasma cholesterol levels could be used as a predictive biomarker for the incidence of Alzheimer's disease. In the present report, we studied the relationship between these two parameters during aging in different transgenic mouse models of Alzheimer's disease, expressing both mutant human amyloid precursor protein and mutant human presenilin-1. Measurements of plasma cholesterol levels revealed a significant reduction in aged APP/PS1 and APP/PS1ki mice, whereas plasma levels in young and aged control mice remained almost unchanged. Furthermore, statistical analysis revealed a significant negative correlation between plasma cholesterol and brain Abeta42 levels during aging in the mice expressing both APP and PS1.
Comment in
-
Serum total cholesterol as a biomarker for Alzheimer's disease: mid-life or late-life determinations?Exp Gerontol. 2006 Sep;41(9):805-6. doi: 10.1016/j.exger.2006.06.005. Epub 2006 Jul 14. Exp Gerontol. 2006. PMID: 16843631 No abstract available.
Similar articles
-
Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.Ann Neurol. 2004 Jun;55(6):801-14. doi: 10.1002/ana.20101. Ann Neurol. 2004. PMID: 15174014
-
Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.Neurobiol Dis. 2006 Sep;23(3):653-62. doi: 10.1016/j.nbd.2006.05.010. Epub 2006 Jul 10. Neurobiol Dis. 2006. PMID: 16829076
-
A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease.Neurobiol Dis. 2001 Oct;8(5):890-9. doi: 10.1006/nbdi.2001.0422. Neurobiol Dis. 2001. PMID: 11592856
-
[Study of pathogenesis of Alzheimer's disease by transgenic mice].Nihon Ronen Igakkai Zasshi. 2000 Jun;37(6):454-7. Nihon Ronen Igakkai Zasshi. 2000. PMID: 10998925 Review. Japanese. No abstract available.
-
[Turning point toward new ageing science].Tanpakushitsu Kakusan Koso. 1998 Apr;43(5):662-8. Tanpakushitsu Kakusan Koso. 1998. PMID: 9564783 Review. Japanese. No abstract available.
Cited by
-
Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.Mol Diagn Ther. 2011 Apr 1;15(2):83-102. doi: 10.1007/BF03256398. Mol Diagn Ther. 2011. PMID: 21623645 Review.
-
Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study.Front Aging Neurosci. 2021 Jul 23;13:713726. doi: 10.3389/fnagi.2021.713726. eCollection 2021. Front Aging Neurosci. 2021. PMID: 34366832 Free PMC article.
-
Biological marker candidates of Alzheimer's disease in blood, plasma, and serum.CNS Neurosci Ther. 2009 Winter;15(4):358-74. doi: 10.1111/j.1755-5949.2009.00104.x. Epub 2009 Oct 14. CNS Neurosci Ther. 2009. PMID: 19840034 Free PMC article. Review.
-
Ceramide and Related-Sphingolipid Levels Are Not Altered in Disease-Associated Brain Regions of APP and APP/PS1 Mouse Models of Alzheimer's Disease: Relationship with the Lack of Neurodegeneration?Int J Alzheimers Dis. 2010 Dec 27;2011:920958. doi: 10.4061/2011/920958. Int J Alzheimers Dis. 2010. PMID: 21234372 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases